Detailed instructions for tilpotide/tilsiparatide (Mufengda) and safety precautions for taking the drug

Tirzepatide, a new dual receptor agonist, can simultaneously activate the glucose-dependent insulin-releasing polypeptide (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, and is therefore classified as a GLP-1/GIP dual agonist. It is mainly used for the treatment of type 2 diabetes and has shown significant weight loss effects in clinical studies. The mechanism of action of tilpotide is to achieve dual management of blood sugar and weight by enhancing insulin secretion, inhibiting postprandial blood sugar rise, delaying gastric emptying and reducing appetite. Its pharmacokinetic properties show that tilpotide has a long half-life and can be injected subcutaneously once a week, providing patients with medication convenience.

When using tilpotide, patients should strictly follow the dosage and medication regimen in the instructions. The starting dose is usually low to observe tolerance and gradually adjust to the therapeutic dose. A common starting dose is 2.5 mg per week, which can be gradually increased to 5 mg based on blood sugar control. >mg, 7.5mg, 10mg or even 15mg. Dose adjustments should be made at least 4 weeks apart to reduce the occurrence of gastrointestinal adverse reactions. Patients should choose the subcutaneous fat site on the abdomen, thigh or upper arm when injecting, and avoid intramuscular or intravenous injection. Before each injection, check whether the liquid is clear and transparent, without particles or discoloration. The injection pen must be properly stored after use to avoid contact with children.

Common adverse reactions of tilpotide are mainly gastrointestinal symptoms, including nausea, vomiting, diarrhea, constipation and loss of appetite. Most symptoms gradually resolve after several weeks of continued use. To reduce side effects, patients can take injections after meals or adjust their diet to avoid high-fat and greasy meals. At the same time, blood sugar levels need to be closely monitored during use, especially when used in combination with other antidiabetic drugs to prevent hypoglycemia. For patients with a history of thyroid disease, pancreatitis or severe gastrointestinal diseases, the risks of use must be assessed under the guidance of a doctor, and necessary laboratory tests and imaging monitoring must be performed.

In addition, tilpotide injection may cause significant weight loss. For patients who are underweight or malnourished, nutritional status and weight changes should be closely monitored. Patients should also regularly monitor liver and kidney function, blood pressure and heart rate to ensure drug safety. Special groups such as pregnant women, lactating women and elderly patients need to fully evaluate the risks and benefits before use, and use it under the guidance of a professional doctor. In terms of storage, unopened tilpotide injection pens need to be refrigerated (2-8°C) to avoid freezing; they can be stored at room temperature after opening, but should be used within the specified time. Patients should strictly abide by the medication instructions during use and not change the dosage or stop medication at will to ensure efficacy and safety.

In summary, tilpotide, as a GLP-1/GIP dual agonist, has shown significant efficacy in blood glucose control and weight loss, and its convenience of once-weekly injection improves patient compliance. During use, it is necessary to follow the principle of gradual dosage, pay attention to gastrointestinal reactions and blood sugar monitoring, and properly inject and store. In particular, special groups need to pay extra attention to risk assessment. Through standardized use and scientific management, tilpotide can exert effective efficacy in patients with type 2 diabetes and related metabolic diseases, while reducing potential adverse reactions and safety risks, providing patients with reliable treatment options.

Reference materials:https://www.drugs.com/tirzepatide.html